{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-250665","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.018658+00:00","generated_at":"2026-06-23T07:30:35.690166+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Phathom Pharmaceuticals appoints James Topper, M.D., Ph.D. to Board of Directors","bullets":["James Topper appointed as Class III director effective September 22, 2022; will serve on nominating and corporate governance committee.","Topper previously served on board from January 2018 to May 2021; currently Managing General Partner at Frazier Life Sciences.","Granted option to purchase 20,000 shares vesting over three years; cash compensation per Non-Employee Director Compensation Program.","Board determined Topper meets Nasdaq independence requirements; no related person transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-250665","json":"https://secwatch.observer/filing/0001193125-22-250665.json","markdown":"https://secwatch.observer/filing/0001193125-22-250665.md","text":"https://secwatch.observer/filing/0001193125-22-250665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/0001193125-22-250665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/d361727d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:30:35.690166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f48f74f21c","claim":"James Topper, M.D., Ph.D. was appointed as Class III Director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/0001193125-22-250665-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}